ViaCyte Interview on Diabetes Stem Cell Trials & Cool Role of Gore-Tex Tech - The Niche
Brendan Smith on LinkedIn: Today, CRISPR Therapeutics and ViaCyte announced that Health Canada
ViaCyte Announces Second Clinical Trial Site at University of Alberta
Xconomy: ViaCyte Reports on Stem Cell Diabetes Trial, Absorbs BetaLogics
ViaCyte (@ViaCyte) / Twitter
ViaCyte Acquires Rights to BetaLogics Assets
Pin on Diabetes
ViaCyte | Regenerative Medicine Therapies for Diabetes
Diabetes Stem Cell Milestone: ViaCyte Transplants 1st Patient - The Niche
CIRM-supported Type I Diabetes treatment enters clinical trials in Europe | The Stem Cellar
Viacyte Receives Funding to Continue Developing Beta Cell Therapies - JDRF
Finally, a possible long-term treatment for type 1 diabetes | UCI Health | Orange County, CA
Will ViaCyte's Encaptra Cell Delivery System 'Cure' Type 1 Diabetes? | Insulin Nation
Practical Cure Project Update: ViaCyte — Juvenile Diabetes Cure Alliance
ViaCyte (@ViaCyte) / Twitter
Stem cell therapies for Type 1 diabetes: current status and proposed road map to guide successful clinical trials - Senior - 2019 - Diabetic Medicine - Wiley Online Library
ViaCyte on Twitter: "Nov. 6: ViaCyte VP, Research and CSO Kevin D'Amour to speak at @ISSCR's “From Stem Cell Biology to New Therapies” https://t.co/f8anGrT6wi #ISSCR #biotech #Toronto #health #T1D #type1diabetes #diabetes #regenerativemedicine #
Breakthrough Technologies for Cell Replacement Therapies for Diabetes| ViaCyte
ViaCyte's Future 'Functional Diabetes Cure' for Diabetes
First Patient Dosed in Phase 1 Clinical Trial for T1D | The Stem Cellar
Clinical trials of stem cell-based "functional cure" for type 1 diabetes underway
CRISPR and ViaCyte dose first subject in Phase I T1D therapy trial
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
JDRF Reports: First-in-Human Gene-Edited Stem Cell Trial? Check.
ViaCyte's Stem Cell-Derived Treatment for Type 1 Diabetes Shows Promising Results in Two Published Studies - ViaCyte
First Human Clinical Trial of Stem Cell-Derived Implants For Type 1 Diabetes
